drugset / Trial / NCT00669591

A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

NCT00669591

Phase 2 Completed 46 enrolled Peregrine Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the overall response to a combination of bavituximab and docetaxel in patients with advanced breast cancer

Timeline

Start
2008-01
Primary completion
2010-06
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bavituximab Monoclonal antibody 3 mg/kg
Background Docetaxel Small molecule

Indications